Holen Sie sich die Stockscreener-App
12.16
5.52%
-0.71
Vorhandelsmarkt:
12.69
0.53
+4.36%
Schlusskurs vom Vortag:
$12.87
Offen:
$12.9
24-Stunden-Volumen:
46,666
Relative Volume:
1.47
Marktkapitalisierung:
$159.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.89M
KGV:
-17.37
EPS:
-0.7
Netto-Cashflow:
$-6.48M
1W Leistung:
+0.83%
1M Leistung:
-1.86%
6M Leistung:
-18.00%
1J Leistung:
+33.23%
1-Tages-Spanne:
$12.03
$12.99
1-Wochen-Bereich:
$12.03
$13.10
52-Wochen-Spanne:
$8.00
$21.44
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Firmenname
Greenwich Lifesciences Inc
Sektor
Branche
Telefon
203-434-3290
Adresse
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Vergleichen Sie GLSI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
12.16 | 159.84M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-01 | Eingeleitet | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Aktie (GLSI) Neueste Nachrichten
Greenwich LifeSciences Provides Update on Commercial Manufacturing - GlobeNewswire
Greenwich LifeSciences Achieves Major Manufacturing Milestone for Breast Cancer Immunotherapy GP2 - StockTitan
Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI) - Marketscreener.com
Long Term Trading Analysis for (GLSI) - Stock Traders Daily
Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01 - GlobeNewswire
Greenwich LifeSciences expands trial sites in Germany - Investing.com India
Greenwich LifeSciences Expands Phase III Cancer Trial with Major German Research Network - StockTitan
Greenwich LifeSciences CEO acquires $31,275 in common stock By Investing.com - Investing.com Australia
Greenwich LifeSciences CEO acquires $31,275 in common stock - Investing.com India
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 2,500 Shares - MarketBeat
Insider Buying: Snehal Patel Acquires Additional Shares of Green - GuruFocus.com
Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France - The Manila Times
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Across France with Unicancer Network - StockTitan
Geode Capital Management LLC Raises Stock Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Barclays PLC Increases Position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Greenwich Lifesciences CEO Snehal Patel buys $39,391 in stock By Investing.com - Investing.com Australia
Insider Buying: Snehal Patel Increases Stake in Greenwich LifeSc - GuruFocus.com
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $24,750.00 in Stock - MarketBeat
Greenwich Lifesciences CEO Snehal Patel buys $39,391 in stock - Investing.com India
Greenwich Lifesciences CEO Snehal Patel acquires $44,030 in stock By Investing.com - Investing.com Canada
Greenwich Lifesciences CEO Snehal Patel acquires $44,030 in stock - Investing.com
Greenwich LifeSciences CEO Snehal Patel buys $23,940 in stock By Investing.com - Investing.com Australia
Snehal Patel Buys 2,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock - MarketBeat
Greenwich LifeSciences CEO Snehal Patel buys $23,940 in stock - Investing.com India
(GLSI) Trading Report - Stock Traders Daily
Greenwich LifeSciences CEO buys $27,264 in company stock By Investing.com - Investing.com Australia
Greenwich LifeSciences CEO buys $27,264 in company stock - Investing.com India
State Street Corp Raises Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Greenwich Lifesciences CEO Snehal Patel acquires $35,584 in stock By Investing.com - Investing.com Canada
Snehal Patel Purchases 3,200 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock - MarketBeat
Greenwich Lifesciences CEO Snehal Patel acquires $35,584 in stock - Investing.com India
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update - MarketBeat
Insider Purchases Worth US$3.19m See Losses As Greenwich LifeSciences Market Value Drops To US$151m - Simply Wall St
How to Take Advantage of moves in (GLSI) - Stock Traders Daily
Greenwich LifeSciences (NASDAQ:GLSI) Reports Results of Annual Meeting - Defense World
Greenwich LifeSciences reports shareholder meeting outcomes By Investing.com - Investing.com Australia
Charles Schwab Investment Management Inc. Has $348,000 Stock Position in Vanguard International High Dividend Yield ETF (NASDAQ:VYMI) - Defense World
Maiden Holdings, Ltd. (NASDAQ:MHLD) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Invesco Dividend Achievers ETF (NASDAQ:PFM) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Sells 3,312 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Charles Schwab Investment Management Inc. Sells 1,210 Shares of Oak Valley Bancorp (NASDAQ:OVLY) - Defense World
Charles Schwab Investment Management Inc. Lowers Position in NexPoint Real Estate Finance, Inc. (NYSE:NREF) - Defense World
Charles Schwab Investment Management Inc. Increases Position in Fresenius Medical Care AG (NYSE:FMS) - Defense World
Charles Schwab Investment Management Inc. Has $351,000 Stock Holdings in Eos Energy Enterprises, Inc. (NASDAQ:EOSE) - Defense World
Seven Hills Realty Trust (NASDAQ:SEVN) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Has $515,000 Stake in Endava plc (NYSE:DAVA) - Defense World
Finanzdaten der Greenwich Lifesciences Inc-Aktie (GLSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):